Clinical Trial: Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis

Brief Summary:

Treatment of reference of severe alcoholic hepatitis is based on corticosteroids, given for 28 days. However, about 25-35% of patients do not take benefit from this treatment and die within the 6 months following the diagnosis. Numerous trials have evaluated the impact of several strategies in association with corticosteroids. None of them has shown an improvement in survival (primary endpoint) as compared to corticosteroids alone.

The project is based on an approach never tested in a randomized controlled trial in severe alcoholic hepatitis, targeting the group of patients at high risk of death (25-35% at 2 months). This approach is based on animal and human studies.Antibiotics are effective in animal models and in other circumstances characterized by liver failure such as gastrointestinal bleeding related to portal hypertension. The interest of studying this population is emphasized by the frequency of infections in these critically ill patients. Antibiotics will be administered before the development of any infection, as it is likely that these patients present with mesenteric bacterial adenitis without systemic signs of infection. Primary endpoint will be 2-month survival as most deaths occur within 60 days and treatment is given for 30 days.

Detailed Summary:

This is a multicenter double-blind randomized controlled study on two parallel groups.

Once inclusion and exclusion criteria verified and after having obtained patient written consent, participative centers will process to inclusion in the trial.

Corticosteroids as well as antibiotics or their placebo will be started orally. Patients will be managed in the hospital unit until day 7, which corresponds to the evaluation of response to treatment using the Lille model. After this 7-day period, patients will be followed-up at day 14, day 21, day 30, day 60 (primary endpoint).

During each visit, biological and clinical features including efficacy and tolerance will be assessed as well as presence of infection and hepatorenal syndrome (secondary endpoints).

Sponsor: University Hospital, Lille

Current Primary Outcome: Patient alive [ Time Frame: at day 60 ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

• Infection [ Time Frame: at day 7, day14, day 21, day 30, day 60; at 3 months, at 6 months ]
  incidence of infection over the 2-month period in the antibiotic+corticosteroid arm as compared to the control arm
• Hepatorenal syndrome [ Time Frame: at day 7, day14, day 21, day 30,at 3 months, at 6 months ]
  incidence of hepatorenal syndrome over the 2-month period in the antibiotic+corticosteroid arm as compared to the control arm
• MELD score <17 [ Time Frame: at day 7, day14, day 21, day 30, ]
  percentage of patients with a low risk of mortality during the first two months (assessed by a MELD score <17) in the two arms of treatment. The MELD score will be calculated using the following formula:(9.57 × log creatinine in milligrams per deciliter) + (3.78 × log bilirubin in milligrams per deciliter) + (11.20 × log international normalized ratio) + 6.43.
• Lille Model [ Time Frame: at day 7, after the first administration of treatment ]
  percentage of patients disclosing a response to treatment assessed by the Lille model (<0.45) in the two arms of treatment.
• Patient alive [ Time Frame: at 3 months, at 6 months ]
  The percentage of patients alive at 2 months in the experimental arm compared to the percentage of patients alive in the control arm

Original Secondary Outcome:

• Infection [ Time Frame: at day 7, day14, day 21, day 30, day 60 ]
  incidence of infection over the 2-month period in the antibiotic+corticosteroid arm as compared to the control arm
• Hepatorenal syndrome [ Time Frame: at day 7, day14, day 21, day 30, ]
  incidence of hepatorenal syndrome over the 2-month period in the antibiotic+corticosteroid arm as compared to the control arm
• MELD score <17 [ Time Frame: at day 7, day14, day 21, day 30, ]
  percentage of patients with a low risk of mortality during the first two months (assessed by a MELD score <17) in the two arms of treatment. The MELD score will be calculated using the following formula:(9.57 × log creatinine in milligrams per deciliter) + (3.78 × log bilirubin in milligrams per deciliter) + (11.20 × log international normalized ratio) + 6.43.
• Lille Model [ Time Frame: at day 7, after the first administration of treatment ]
  percentage of patients disclosing a response to treatment assessed by the Lille model (<0.45) in the two arms of treatment.

Information By: University Hospital, Lille

Dates:
Date Received: October 28, 2014
Date Started: June 13, 2015
Date Completion: December 2018
Last Updated: May 18, 2017
Last Verified: May 2017